The investigators recruited 83 women diagnosed with polycystic ovary syndrome from the gynecology clinic of the Gonabad referral hospital and from private gynecology practices, alongside 88 healthy controls, during 2025. Participants were selected through convenience sampling, and each completed a structured demographic and social determinants of health checklist as well as three validated instruments: the Health Literacy Questionnaire, the Multidimensional Scale of Perceived Social Support, and the Household Food Insecurity Access Scale. Statistical analysis was performed in R version 4.6.1, with the significance threshold set at p less than 0.05. The two groups were demographically comparable in age, averaging roughly 27 years in the syndrome group and 28 years among controls, which allowed the researchers to focus on social and clinical contrasts rather than age effects.

The descriptive findings alone were striking. Women with the syndrome had grown up in poorer households, were more likely to be renting their current homes, and lived in dwellings with fewer rooms than the comparison group, differences that were statistically significant across the board. Intriguingly, the syndrome group rated their neighborhoods as having better green space and better safety, an apparent paradox the authors address through the multivariate analysis. Body mass index was significantly higher among affected women, and the smoking gap was dramatic: 41.0 percent of women with the syndrome reported smoking, compared with just 11.4 percent of controls, a nearly fourfold difference that reached high statistical significance with a p value below 0.001.

Family history painted a consistent picture of inherited and shared metabolic vulnerability. Women with the syndrome were significantly more likely to report relatives with polycystic ovary syndrome itself, with diabetes, and with hyperlipidemia, all differences surviving statistical testing. Health literacy scores were also higher in the syndrome group, plausibly because a chronic diagnosis prompts patients to seek out medical information. Food insecurity, measured by the Household Food Insecurity Access Scale, was actually lower in the affected group, and perceived social support did not differ between the two cohorts, suggesting that the social gradients in this condition operate through specific channels rather than through generalized deprivation.

When the team moved from simple comparisons to multivariate logistic regression, the independent risk factors crystallized. Lacking access to green space carried an odds ratio of 12.80 for having the syndrome, the largest effect in the model, followed closely by living in an unsafe neighborhood at an odds ratio of 12.31. A positive family history of the syndrome raised the odds nearly sevenfold at 6.89, smoking raised them 5.62-fold, familial hyperlipidemia 3.66-fold, and each additional parity increased the odds by 1.76 times. These estimates were adjusted for one another, meaning each factor contributed information the others could not explain away.

Equally notable were the protective associations. Women who described their childhood economic status as moderate had 80 percent lower odds of the syndrome than the reference group, with an odds ratio of 0.20, and those who described it as low had odds of just 0.11. Being married was also associated with reduced odds, at 0.23. The authors interpret the childhood economics finding with caution: in this Iranian setting, lower-income households may involve higher physical activity levels, different dietary patterns, or earlier life exposures that alter metabolic trajectories, and the cross-sectional design cannot establish direction. Nonetheless, the finding challenges the assumption that disadvantage always tracks with higher disease burden, and it underscores how context-specific the social epidemiology of endocrine disorders can be.

Mechanistically, the connections between these social factors and ovarian endocrine dysfunction are biologically plausible. Chronic stress from living in unsafe neighborhoods sustains sympathetic nervous system and hypothalamic-pituitary-adrenal activation, which can disturb gonadotropin secretion and ovarian steroidogenesis. Smoking delivers both oxidative stress and endocrine disruption, with nicotine and combustion byproducts implicated in altered androgen metabolism and impaired follicular development. Hyperlipidemia within families points to shared genetic and dietary determinants of insulin resistance, the metabolic hub around which much of polycystic ovary syndrome pathology revolves. Green space, meanwhile, has been repeatedly linked in environmental health research to lower stress, better air quality and higher physical activity, each of which can modulate insulin sensitivity and, in turn, ovarian function.

The renaming of the condition to polyendocrine metabolic ovarian syndrome, adopted recently by expert consensus, reflects exactly this broadened understanding: the syndrome is no longer viewed as a purely ovarian disorder but as a systemic endocrine-metabolic condition with reproductive consequences. The present study extends that reframing in a social direction, situating the syndrome within the same determinants-of-health framework long applied to cardiovascular disease and diabetes. If neighborhood safety and green access carry odds ratios comparable to those of established familial risk factors, the authors argue, then clinicians and policymakers may need to consider environmental interventions alongside conventional medical management.

Several limitations temper the findings, and the authors acknowledge them. The case-control design identifies associations, not causes, and the temporal ordering between social exposures and disease onset cannot be confirmed. Convenience sampling from a single city and its surrounding clinics limits generalizability, and the modest sample size of 171 women yields the wide confidence intervals typical of small multivariate models. Self-reported smoking, family history and neighborhood perceptions are also vulnerable to recall and reporting bias, and residual confounding by unmeasured variables, from dietary composition to polycystic ovary morphology criteria used in diagnosis, remains possible. The study was funded by Gonabad University of Medical Sciences under grant 1678 and approved by that institution’s ethics committee under code IR.GMU.REC.1402.167, with informed consent obtained from all participants.

Even with those caveats, the study is among the first to quantify how a constellation of social determinants, from childhood poverty to tree-lined streets, tracks with one of the most common endocrine disorders of reproductive-age women, which affects an estimated one in ten worldwide. The message resonating through the data is that reproductive endocrinology cannot be practiced in isolation from sociology. A woman’s odds of developing this syndrome appear to be written not only in her genome but in the safety of her streets, the smoke she inhales, the children she has borne and the economic circumstances of her childhood. For researchers, the findings open a clear agenda: longitudinal cohorts that can disentangle whether unsafe neighborhoods and scarce green space truly help cause ovarian endocrine dysfunction, and whether environmental improvements could shift those odds. For the millions of women living with the condition, the research affirms that its roots may reach well beyond the ovary.

Subject of Research: Association between social determinants of health and polycystic ovary syndrome risk in a case-control study of reproductive-age women

Article Title: Association of social determinants of health with polycystic ovary syndrome: evidence from a case-control study

Article References: Dashti, S., Kosari, M., Mahmoudian, A., Eghbalian, M., Seyedeh, N., & Bahri, N. (2026). Association of social determinants of health with polycystic ovary syndrome: evidence from a case-control study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02263-y

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02263-y

Keywords: polycystic ovary syndrome, PCOS, social determinants of health, smoking, neighborhood safety, green space, hyperlipidemia, health literacy, food insecurity, case-control study, reproductive endocrinology, Iran

PCOS is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular ovulation, clinical or biochemical signs of elevated androgens, and the presence of polycystic ovarian morphology. A hallmark of the condition is an excess of small, arrested follicles that fail to reach developmental maturity, a phenomenon known as follicular arrest. Anti-Müllerian hormone, or AMH, is often elevated in PCOS patients because of the abundance of small growing follicles, and it has become a valuable biomarker for diagnosis and disease severity. Yet the cellular reasons why these follicles stall remain incompletely understood. Because granulosa cells supply the developing follicle with energy, growth factors, and vascular signals, they represent a logical place to look for the roots of this arrest.

To investigate, the team isolated granulosa cells from women undergoing in vitro fertilization at a single center, applying the Rotterdam criteria to diagnose PCOS. The final cohort consisted of a control group of twelve women whose serum AMH levels fell within the normal range of 2 to 5 nanograms per milliliter, and a PCOS group of eleven women who met the Rotterdam criteria and displayed elevated AMH above 5 nanograms per milliliter. To control for the possibility that differences might simply reflect follicle size rather than disease, the researchers further subdivided cells from both groups according to follicular diameter, comparing cells from large follicles exceeding 14 millimeters with those from small follicles under 14 millimeters. All cells were cultured under standardized laboratory conditions, allowing the team to compare morphology, proliferation, mitochondrial activity, and secretory function directly.

The results were consistent across several independent lines of measurement. Under the microscope, PCOS-derived granulosa cells displayed abnormal morphology and an enlarged cell size compared with cells from healthy controls. When their capacity to divide was assessed, the PCOS cells proliferated significantly more slowly. This impaired growth is particularly consequential because granulosa cell proliferation drives follicle expansion during development; cells that cannot multiply properly cannot support a follicle’s progression toward ovulation. The finding suggests that the follicular arrest characteristic of PCOS may begin within the somatic compartment of the follicle rather than being solely an oocyte problem.

Deeper analysis revealed where the cellular failure likely originates: the mitochondria. These organelles serve as the cell’s power plants, generating adenosine triphosphate, or ATP, the chemical currency that fuels virtually every energy-demanding process, including cell division, protein synthesis, and secretion. The researchers found that both mitochondrial function and intracellular ATP levels were significantly reduced in PCOS granulosa cells. This energy deficit provides a coherent explanation for the observed proliferation defect, as cells with insufficient ATP cannot sustain the biosynthetic workload required to replicate. Mitochondrial dysfunction in granulosa cells has been suspected in PCOS before, but linking it quantitatively to both proliferative failure and secretory impairment in the same cohort strengthens the case that it is a central defect rather than an incidental finding.

Perhaps the most novel component of the study concerns angiogenesis, the formation of new blood vessels, which is essential for follicle development. A growing follicle depends on a rich vascular network to receive oxygen, nutrients, and hormones from the bloodstream. Granulosa cells contribute to building this network indirectly through paracrine signaling, releasing factors that stimulate nearby endothelial cells to organize into vessel structures. To test this function, the team collected conditioned media, essentially the liquid culture environment in which the granulosa cells had been growing, and applied it to human umbilical vein endothelial cells in a tube formation assay, a standard laboratory test of angiogenic capacity. The conditioned media from PCOS granulosa cells significantly impaired the ability of endothelial cells to form tubes, demonstrating that the angiogenic support normally provided by these ovarian cells was diminished in the disease state.

The effect was not uniform across follicle sizes. Granulosa cells harvested from larger follicles showed a more pronounced impairment in angiogenic support than those from smaller follicles, an observation that could help explain why larger follicles in PCOS ovaries so often fail to progress to ovulation despite reaching substantial size. At the molecular level, the researchers examined the expression of angiogenesis-related cytokines and found that three key pro-angiogenic chemokines, CXCL6, IL8, and MCP1, were consistently downregulated in PCOS granulosa cells. Interestingly, vascular endothelial growth factor A, or VEGF-A, the most famous angiogenic factor, showed a less consistent pattern, suggesting that the angiogenic deficit in PCOS is not simply a matter of reduced VEGF but rather a broader disruption of the chemokine-mediated signaling network that coordinates blood vessel formation.

Taken together, the findings sketch a coherent mechanistic framework for how PCOS disrupts follicle development. Mitochondrial dysfunction reduces ATP availability, which in turn limits cellular proliferation and dampens the secretion of angiogenic chemokines. Reduced angiogenic signaling compromises the vascular supply to developing follicles, depriving both the granulosa cells and the oocyte of the metabolic support needed for maturation. The authors describe this as a functional interplay between metabolic dysfunction and disrupted chemokine-mediated angiogenic signaling, a chain of causation that connects the metabolic phenotype of PCOS to its reproductive consequences. Because the chemokines CXCL6, IL8, and MCP1 emerged as consistently downregulated factors, they represent plausible targets for interventions aimed at restoring follicular vascular support in affected women.

The study carries practical implications for fertility medicine. Many women with PCOS require assisted reproductive technology to conceive, and the quality of the follicular environment is a determinant of oocyte competence and embryo development. If the granulosa cell dysfunction identified here proves to be modifiable, strategies to improve mitochondrial function or replenish angiogenic chemokine signaling could theoretically enhance follicle quality in PCOS patients undergoing IVF. Such approaches remain speculative, and the study is a relatively small observational analysis conducted at a single center, so the findings will need replication in larger and more diverse cohorts before they translate into clinical protocols. The authors note that the work provides potential targets for improving reproductive outcomes rather than an immediate treatment.

Beyond its clinical relevance, the study contributes to a growing appreciation of the ovary as a metabolically demanding organ in which cellular energy status and developmental signaling are tightly intertwined. The follicle is often studied primarily through its hormonal and genetic regulation, but this research underscores that the physical infrastructure of follicle growth, from mitochondrial ATP production to the surrounding vasculature, may be equally decisive. For the millions of women living with PCOS worldwide, a condition that remains among the leading causes of anovulatory infertility, understanding that their follicles may be starved of both energy and vascular support offers a new dimension to the search for causes and cures. As research continues to map the molecular pathways linking mitochondrial health, chemokine signaling, and folliculogenesis, the granulosa cell may well emerge as a key gateway through which future therapies for PCOS are delivered.

The study was conducted under ethical oversight at Cathay General Hospital in Taipei, with approval from the hospital’s Ethics Committee and written informed consent obtained from all participants, in accordance with the Declaration of Helsinki. The work received financial support from the National Science and Technology Council of Taiwan and from Cathay General Hospital, and the authors declared no competing interests.

Readers should note that the article was published as an accepted manuscript in open access form, released early to provide faster access to peer-reviewed research. This version is citable and carries a permanent DOI, though it remains subject to editorial revisions before the final Version of Record replaces it. The research is categorized under topics including endocrine reproductive disorders, fertility, and gonadal disorders, reflecting its position at the intersection of reproductive endocrinology and cellular metabolism research.

Subject of Research: Mitochondrial dysfunction in granulosa cells is associated with impaired proliferation and angiogenic support in women with polycystic ovarian syndrome and elevated AMH

Article Title: Mitochondrial dysfunction in granulosa cells is associated with impaired proliferation and angiogenic support in women with polycystic ovarian syndrome and elevated AMH

Article References: Hong, K.-J., Lin, J.-J., & Lai, T.-H. (2026). Mitochondrial dysfunction in granulosa cells is associated with impaired proliferation and angiogenic support in women with polycystic ovarian syndrome and elevated AMH. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02264-x

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02264-x

Keywords: Mitochondrial, dysfunction, granulosa, cells, associated, impaired, proliferation, angiogenic, support, women, polycystic, ovarian

Unexplained recurrent spontaneous abortion, typically defined as two or more consecutive pregnancy losses with no identifiable cause, affects an estimated one to five percent of reproductive-age women. For many, no chromosomal, anatomical, hormonal or thrombotic explanation is ever found, leaving both patients and physicians without a clear therapeutic target. In recent years, however, growing evidence has implicated insulin resistance as a modifiable contributor. Insulin resistance, in which the body’s tissues respond poorly to the hormone insulin, is common in conditions such as polycystic ovary syndrome and type 2 diabetes, and it is thought to disturb the delicate metabolic environment required for successful embryo implantation and early placental development.

The standard screening tool for insulin resistance in clinical practice is the homeostasis model assessment of insulin resistance, or HOMA-IR, an index calculated from fasting blood glucose and fasting insulin concentrations. Although convenient in principle, HOMA-IR has practical drawbacks in busy reproductive clinics. Because the calculation requires both measurements to be taken after an overnight fast, patients must return for a dedicated morning blood draw, adding inconvenience, cost and delay. Moreover, HOMA-IR is itself only a surrogate; the true gold standard for quantifying insulin sensitivity, the hyperinsulinaemic–euglycaemic clamp, is far too labor-intensive for routine care. The research team, led by Lujing Chen, Feiyan Li and Yacong Cao with senior authors Yihong Guo, Hui Chen and Ping Zhou, set out to determine whether serum adiponectin could serve as an adjunctive flag for insulin resistance in this specific and vulnerable patient population.

Adiponectin is an attractive candidate for several reasons. Unlike many circulating biomarkers, it is almost exclusively produced by adipose tissue, and it acts directly to enhance insulin sensitivity in liver and skeletal muscle through activation of AMP-activated protein kinase and related signaling pathways. Critically for screening purposes, adiponectin concentrations exhibit low biological variability and minimal post-prandial fluctuation, meaning they remain relatively stable throughout the day and are less affected by recent meals than glucose or insulin measurements. Levels tend to fall as insulin resistance worsens, providing an inverse window into metabolic health.

The study was a single-centre retrospective observational analysis of women managed for unexplained recurrent spontaneous abortion at the tertiary maternal and child health hospital in Dongguan, in southern China’s Guangdong province. All 404 participants were of Chinese Han ethnicity; 346 were non-pregnant and 58 were in early pregnancy. Serum total adiponectin was quantified using latex-enhanced immunoturbidimetry on a Hitachi 7180 automated analyser, a robust platform with an intra-assay coefficient of variation of 3.2 percent and an inter-assay coefficient of variation of 5.1 percent. Insulin resistance was defined as a HOMA-IR value of 2.41 or greater, and adiponectin was measured from the fasting blood sample obtained during the participants’ oral glucose tolerance testing. The researchers deliberately designated the non-pregnant subgroup of 346 women as the primary analysis population, since pregnancy itself alters both insulin sensitivity and adipokine profiles, with the full cohort analysed secondarily.

The results were strikingly consistent. Half of the cohort, 203 of the 404 women, met the criterion for insulin resistance. Serum adiponectin was significantly lower in the insulin-resistant group than in the insulin-sensitive group, with a median of 6.40 micrograms per milliliter in the resistant group compared with 8.50 micrograms per milliliter in the non-resistant group, a difference that was highly statistically significant. Across the entire cohort, adiponectin showed a clear inverse correlation with HOMA-IR, with a Spearman correlation coefficient of minus 0.455, and adiponectin levels declined in a graded fashion across ascending quartiles of HOMA-IR, confirming a dose–response relationship between worsening insulin resistance and falling adiponectin.

Beyond correlation, the team asked whether adiponectin could actually discriminate between insulin-resistant and insulin-sensitive women, and whether it added information beyond what age and body mass index already provide. In the primary non-pregnant analysis, adiponectin alone yielded an area under the receiver operating characteristic curve of 0.733, indicating moderate discriminative ability, and a similar value of 0.711 in the full cohort. Adding adiponectin to a statistical model containing age and body mass index increased the area under the curve from 0.759 to 0.788, an improvement that reached statistical significance on formal DeLong testing. The optimal diagnostic threshold, identified by maximizing the Youden index, was an adiponectin concentration of 6.60 micrograms per milliliter or lower. At this cut-off, the test achieved a sensitivity of 58.3 percent but a specificity of 78.7 percent, together with a positive predictive value of 72.1 percent, a negative predictive value of 66.7 percent and a positive likelihood ratio of 2.73. In other words, a low adiponectin result makes insulin resistance substantially more likely and is reliable when it points toward the diagnosis, even though it will miss a proportion of affected women.

The robustness of the association held up under scrutiny. When the researchers repeated their analyses using alternative HOMA-IR thresholds of 2.0, 2.5 and 3.0, the area under the curve for adiponectin remained within a narrow and consistent range of 0.697 to 0.724, indicating that the marker’s performance does not depend on the precise definition of insulin resistance chosen. Multivariable logistic regression, adjusting for age, body mass index and pregnancy status, confirmed that adiponectin is independently associated with insulin resistance: each 1 microgram per milliliter decrease in adiponectin concentration was associated with a 17 percent increase in the odds of insulin resistance, with an adjusted odds ratio of 1.17.

The clinical logic of the proposed approach is one of triage rather than replacement. Because adiponectin’s specificity outweighs its sensitivity, a low result could reasonably raise suspicion and prompt confirmatory fasting glucose and insulin testing, while a normal result would not by itself exclude insulin resistance. For women already undergoing oral glucose tolerance testing as part of recurrent pregnancy loss workups, the additional adiponectin measurement requires no extra blood draw and no extra fasting visit, since it can be run on the same fasting sample. This practicality is precisely what makes the marker appealing in resource-conscious reproductive clinics, where streamlining the diagnostic pathway for insulin resistance could accelerate the identification of a treatable contributor to pregnancy loss.

The authors are careful to frame their conclusions within the limits of the study design. This was a retrospective, single-centre investigation conducted in a homogeneous Chinese Han population, and its cross-sectional nature means it demonstrates association rather than causation. Importantly, the study does not show that adiponectin predicts pregnancy prognosis, nor that management guided by adiponectin levels improves reproductive outcomes. The researchers emphasize that prospective validation in independent, more diverse cohorts is required before adiponectin can be recommended as a clinical triage marker in routine care. If such validation succeeds, however, the implications could extend beyond recurrent miscarriage, since adiponectin’s stability and assay accessibility make it a candidate for metabolic screening in other reproductive contexts, including polycystic ovary syndrome and pregestational diabetes care.

For the millions of women worldwide who endure the heartbreak of unexplained pregnancy loss, the prospect of uncovering a modifiable metabolic driver is deeply significant. Insulin resistance, unlike genetic or immunological causes, can often be addressed through lifestyle intervention and established medications, potentially converting a hopeless diagnosis into a manageable one. This study adds a plausible, low-cost tool to the diagnostic toolkit, suggesting that a hormone long studied in obesity and diabetes research may deserve a place in the reproductive medicine clinic. The road from retrospective biomarker analysis to validated clinical practice is long, but the direction of travel, from adipose tissue biology to better care for women who have suffered repeated pregnancy loss, is now clearly marked.